We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

154 hedge funds and large institutions have $774M invested in Ocular Therapeutix in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

22% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 45

12% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $9.14M

3% more funds holding

Funds holding: 149 → 154 (+5)

4.87% less ownership

Funds ownership: 66.98% → 62.11% (-4.9%)

26% less capital invested

Capital invested by funds: $1.04B → $774M (-$269M)

60% less funds holding in top 10

Funds holding in top 10: 10 → 4 (-6)

Holders
154
Holders Change
+5
Holders Change %
+3.36%
% of All Funds
2.7%
Holding in Top 10
4
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-60%
% of All Funds
0.07%
New
25
Increased
55
Reduced
45
Closed
18
Calls
$10.3M
Puts
$9.14M
Net Calls
+$1.12M
Net Calls Change
-$6.19M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$8.9M
2
RCMNY
Rubric Capital Management (New York)
New York
+$7.36M
3
KSCM
Kamunting Street Capital Management
Florida
+$7.06M
4
BlackRock
BlackRock
New York
+$6.83M
5
Two Sigma Investments
Two Sigma Investments
New York
+$4.78M

Top Sellers

Rank Fund Capital Flow
1
VVM
Versant Venture Management
California
-$30.3M
2
Citadel Advisors
Citadel Advisors
Florida
-$28.5M
3
Invesco
Invesco
Georgia
-$18.1M
4
DCM
Driehaus Capital Management
Illinois
-$17.4M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$7.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$5.49M +$1.39M +72,409 +28%
ACM
27
Altium Capital Management
New York
$5.31M +$443K +23,000 +8%
Federated Hermes
28
Federated Hermes
Pennsylvania
$5.14M +$1.24M +64,327 +26%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$4.23M -$1.26M -65,394 -20%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$4.22M +$1.48M +77,063 +43%
N
31
Nuveen
North Carolina
$4.18M -$6.66M -345,720 -58%
Charles Schwab
32
Charles Schwab
California
$3.98M +$1.42M +73,657 +44%
AAA
33
Affinity Asset Advisors
New York
$3.73M +$144K +7,500 +3%
LCG
34
Lisanti Capital Growth
New York
$3.2M -$3.3M -171,240 -47%
NA
35
Nottingham Advisors
New York
$3.19M -$28.9K -1,500 -0.8%
Millennium Management
36
Millennium Management
New York
$3.19M +$3.74M +194,295 New
Fidelity Investments
37
Fidelity Investments
Massachusetts
$3.03M -$116 -6 -0%
Swiss National Bank
38
Swiss National Bank
Switzerland
$2.27M +$28.9K +1,500 +1%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$2.02M -$277K -14,381 -10%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$1.8M +$119K +6,195 +6%
Citadel Advisors
41
Citadel Advisors
Florida
$1.77M -$28.5M -1,480,793 -93%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$1.67M +$27K +1,400 +1%
QP
43
Quilter Plc
United Kingdom
$1.61M +$3.37K +175 +0.2%
Assenagon Asset Management
44
Assenagon Asset Management
Luxembourg
$1.57M – – –
Brown Advisory
45
Brown Advisory
Maryland
$1.48M +$1.73M +90,000 New
SEI Investments
46
SEI Investments
Pennsylvania
$1.48M +$368K +19,130 +34%
AllianceBernstein
47
AllianceBernstein
Tennessee
$1.42M +$42.4K +2,200 +3%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$1.37M -$42.2K -2,189 -3%
US Bancorp
49
US Bancorp
Minnesota
$1.36M – – –
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$1.31M -$117K -6,080 -7%
1
2
3 4 5

OCUL Hedge Fund Activity: Q1 2021 in Review

154 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2021, worth a combined $774M — down 26% from $1.04B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new OCUL positions and 18 closed out — a net gain of 7 holders — while 55 added to existing stakes and 45 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $8.9M. The largest seller was Versant Venture Management, exiting entirely with an estimated $30.3M sold.

  • 154 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2021, up from 149 in Q4 2020.
  • Funds reported $774M of Ocular Therapeutix stock for Q1 2021, down 26% quarter-over-quarter.
  • 25 funds opened new Ocular Therapeutix positions in Q1 2021 and 18 closed out, a net change of +7 holders.
  • The largest Ocular Therapeutix buyer in Q1 2021 was Victory Capital Management, an estimated $8.9M added.
  • The largest Ocular Therapeutix seller in Q1 2021 was Versant Venture Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q1 2021.